» Articles » PMID: 28644687

Massive Paracetamol Overdose: an Observational Study of the Effect of Activated Charcoal and Increased Acetylcysteine Dose (ATOM-2)

Overview
Publisher Informa Healthcare
Specialty Toxicology
Date 2017 Jun 24
PMID 28644687
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Paracetamol is commonly taken in overdose, with increasing concerns that those taking "massive" overdoses have higher rates of hepatotoxicity and may require higher doses of acetylcysteine. The objective was to describe the clinical characteristics and outcomes of "massive" (≥ 40 g) paracetamol overdoses.

Methods: Patients were identified through the Australian Paracetamol Project, a prospective observational study through Poisons Information Centres in NSW and Queensland, over 3 and 1.5 years, respectively, and retrospectively from three clinical toxicology unit databases (over 2.5 to 20 years). Included were immediate-release paracetamol overdoses ≥ 40 g ingested over ≤ 8 h. Outcomes measured included paracetamol ratio[defined as the ratio of the first paracetamol concentration taken 4-16 h post-ingestion to the standard (150 mg/L at 4 h) nomogram line at that time] and hepatotoxicity (ALT >1000 U/L).

Results: Two hundred paracetamol overdoses were analysed, reported median dose ingested was 50 g (interquartile range (IQR): 45-60 g) and median paracetamol ratio 1.9 (IQR: 1.4-2.9, n = 173). One hundred and ninety-three received acetylcysteine at median time of 6.3 h (IQR: 4-9.3 h) post-ingestion. Twenty-eight (14%) developed hepatotoxicity, including six treated within 8 h of ingestion. Activated charcoal was administered to 49(25%), at median of 2 h post-ingestion (IQR:1.5-5 h). Those receiving activated charcoal (within 4 h of ingestion), had significantly lower paracetamol ratio versus those who did not: 1.4 (n = 33, IQR: 1.1-1.6) versus 2.2 (n = 140, IQR: 1.5-3.0) (p < .0001) (paracetamol concentration measured ≥ 1 h after charcoal). Furthermore, they had lower rates of hepatotoxicity [unadjusted OR: 0.12 (95% CI: <0.001-0.91); adjusted for time to acetylcysteine OR: 0.20 (95%CI: 0.002-1.74)]. Seventy-nine had a paracetamol ratio ≥2, 43 received an increased dose of acetylcysteine in the first 21 h; most commonly a double dose in the last bag (100 to 200 mg/kg/16 h). Those receiving increased acetylcysteine had a significant decrease risk of hepatotoxicity [OR:0.27 (95% CI: 0.08-0.94)]. The OR remained similar after adjustment for time to acetylcysteine and paracetamol ratio.

Conclusion: Massive paracetamol overdose can result in hepatotoxicity despite early treatment. Paracetamol concentrations were markedly reduced in those receiving activated charcoal within 4 h. In those with high paracetamol concentrations, treatment with increased acetylcysteine dose within 21 h was associated with a significant reduction in hepatotoxicity.

Citing Articles

Should high-dose N-acetylcysteine be given in cases of massive paracetamol overdoses: A narrative review.

Erichsen P, Dalhoff K, Andersen M Basic Clin Pharmacol Toxicol. 2024; 135(3):285-294.

PMID: 39004668 DOI: 10.1111/bcpt.14051.


The Evolution of Circulating Biomarkers for Use in Acetaminophen/Paracetamol-Induced Liver Injury in Humans: A Scoping Review.

McGill M, Curry S Livers. 2024; 3(4):569-596.

PMID: 38434489 PMC: 10906739. DOI: 10.3390/livers3040039.


Single cell RNA-sequencing analysis reveals that -acetylcysteine partially reverses hepatic immune dysfunction in biliary atresia.

Ye R, Ma S, Chen Y, Shan J, Tan L, Su L JHEP Rep. 2023; 5(11):100908.

PMID: 37869073 PMC: 10585304. DOI: 10.1016/j.jhepr.2023.100908.


Acetaminophen Metabolites on Presentation Following an Acute Acetaminophen Overdose (ATOM-7).

Chiew A, Isbister G, Stathakis P, Isoardi K, Page C, Ress K Clin Pharmacol Ther. 2023; 113(6):1304-1314.

PMID: 36919638 PMC: 10952325. DOI: 10.1002/cpt.2888.


Successful management of delayed presentation of massive paracetamol overdose in a resource-limited setting: A case report from Nepal.

Lamichhane P, Pokhrel K, Bhandari B, Agrawal A, Ghimire B, Shilpakar O Clin Case Rep. 2022; 10(12):e6733.

PMID: 36523377 PMC: 9744716. DOI: 10.1002/ccr3.6733.